



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Comparative Efficacy of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Treatment of Macular Oedema Secondary to Central Retinal Vein Occlusion

Systematic Review

*For Partial Fulfillment of Master Degree in
Ophthalmology*

By

Noura Hashem Hashem

Bachelor of medicine and surgery Ain shams University

Supervised By

Prof. Dr. Abd El Rahman Gaber Salman

Professor of Ophthalmology

Faculty of Medicine Ain Shams University

Dr. Weam Mohamed Ebeid

Assistant Professor of Ophthalmology

Faculty of Medicine Ain Shams University

Dr. Noureldin Hussein Abozeid

Lecturer of Ophthalmology

Faculty of Medicine Ain Shams University

*Faculty of Medicine
Ain Shams University*

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَدَّانِكَ لَا مَعْلَمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٢٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Abd El Rahman Gaber Salman**, Professor of Ophthalmology, Faculty of Medicine Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Weam Mohamed Ebeid**, Assistant Professor of Ophthalmology, Faculty of Medicine Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Moueldin Hussein Abozeid**, Lecturer of Ophthalmology, Faculty of Medicine Ain Shams University, for his great help, active participation and guidance.*

Noura Hashem

List of Contents

Title	Page No.
List of Abbreviations.....	i
List of Tables	iii
List of Figures	v
Introduction	1
Aim of the Study	2
Review of Literature	3
Methodology.....	39
Results	44
Discussion	74
Summary	80
Conclusion	83
References	84
Arabic Summary	—

List of Abbreviations

Abb.	Full term
AMD	Age related macular degeneration
Ang-2	Angiopoietin-2
Anti-VEGF	Antivascular endothelial growth factor
BCVA.....	Bestcorrected visual acuity
BRVO.....	Branch retinal vein occlusion
CRA	Central retinal artery
CRT.....	Central retinal thickness
CRV	Central retinal vein
CRVO.....	Central retinal vein occlusion
DCP	Deep capillary plexus
DME	Diabetic macular edema
DRIL.....	Disorganization of the retinal inner layers
ETDRS.....	Early Treatment Diabetic Retinopathy Study
EZ	Ellipsoid zone
FA	Fluorescein angiography
FAZ.....	Fovea avascular zone
FcRn	Neonatal Fc Receptor
FDA	Food and Drug Administration
IL	Interleukin
ILM	Inner limiting membrane
ME	Macular edema
n-AMD	Neovascular age related macular degeneration
NPAS	Non-perfusion areas
NVD	Neovascularization of the disc
NVE	Neovascularization elsewhere

List of Abbreviations Cont...

Abb.	Full term
OCT	Optical coherence tomography
OCTA	Optical coherence tomography angiography
OVCS.....	Optic disc venous collaterals
PIGF	Placenta growth factor
PK	Population pharmacokinetic
PRN	Pro re nata
PRISMA.....	Preferred Reporting Items for Systematic Reviews and Meta-analyses
RCT.....	Randomized control trials
RVO	Retinal vein occlusion
SAES	Serious adverse events
SCP	Superficial capillary plexus
VA.....	Visual acuity
VEGF	Vascular endothelial growth factor

List of Tables

Table No.	Title	Page No.
Table (1):	Number of eyes and study characteristics	45
Table (2):	Summary of patient's characteristics	46
Table (3):	Summary of baseline patient's characteristics	47
Table (4):	Summary of efficacy treatment outcomes in all studies	48
Table (5):	Summary of safety treatment outcomes in all studies	49
Table (6):	Meta-analysis of (average BCVA) on Aflibercept group vs Control group – Mean difference	52
Table (7):	Meta-analysis of (average CRT decrease) on Aflibercept group vs Control group – Mean difference	54
Table (8):	Meta-analysis of (recurrence rate) on Aflibercept group vs Control group - Odds Ratio.....	56
Table (9):	Meta-analysis of (complications rate) on Aflibercept group vs Control group - Odds Ratio.....	58
Table (10):	Meta-analysis of (average BCVA) on Bevacizumab group vs Control group – Mean difference.....	60
Table (11):	Meta-analysis of (average CRT decrease) on Bevacizumab group vs control group – Mean difference	62
Table (12):	Meta-analysis of (complications rate) on Bevacizumab group vs Control group - Odds Ratio.....	64

List of Tables Cont...

Table No.	Title	Page No.
Table (13):	Meta-analysis of (average BCVA) on Ranibizumab group vs Control group – Mean difference.....	66
Table (14):	Meta-analysis of (average CRT decrease) on Ranibizumab group vs control group – Mean difference	68
Table (15):	Meta-analysis of (complications rate) on Ranibizumab group vs Control group - Odds Ratio.....	70
Table (16):	Multiple regression model for the Factors affecting BCVA improvement using Forward method.....	73
Table (17):	Multiple regression model for the Factors affecting CRT improvement using Forward method.....	73

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Ophthalmoscopic view of the normal retina	3
Fig. (2):	Topographic Anatomy of Normal Macula.	5
Fig. (3):	Histological Layering of the Macula.....	6
Fig. (4):	Vertical Section of Human Fovea.....	6
Fig. (5):	Fundus photograph showing fluorescein imaging of the major arteries and veins in a normal human right eye retina	9
Fig. (6):	Macular edema in a 75-year-old woman with CRVO	16
Fig. (7):	OCT map (650 × 325) in a case of central retinal vein occlusion	16
Fig. (8):	Fluorescein angiogram of a patient with nonischemic central retinal vein occlusion, showing staining of dilated tortuous veins with leakage into macula in a cystoid pattern.....	17
Fig. (9):	Fluorescein angiogram of the same patient as in previous image, showing perifoveal capillary leakage in a cystoid pattern in late phases of angiogram.....	17
Fig. (10):	Late phase of fluorescein angiograph of the same patient as in previous image, showing cystoid pattern of leakage from perifoveal dilated leaking capillary network	18
Fig. (11):	Arteriovenous phase of fluorescein angiograph showing perifoveal capillary leakage in a patient with nonischemic central retinal vein occlusion	19
Fig. (12):	OCTA of the retina and Histological section of the retina showing the retinal layers (center).....	20

List of Figures Cont...

Fig. No.	Title	Page No.
Fig. (13):	OCTA (3 × 3 mm) in a case of CRVO.....	22
Fig. (14):	PRISMA flow chart for study selection.....	44
Fig. (15):	Forest plot of (BCVA) on Aflibercept group vs Control group - Mean difference.....	53
Fig. (16):	Funnel plot of (BCVA) on Aflibercept group vs Control group - Mean difference (publication bias was non-significant).	53
Fig. (17):	Forest plot of (CRT decrease) on Aflibercept group vs Control group - Mean difference.....	55
Fig. (18):	Funnel plot of (CRT decrease) on Aflibercept group vs Control group - Mean difference (publication bias was significant).....	55
Fig. (19):	Forest plot of (recurrence rate) on Aflibercept group vs Control group – Odds Ratio.	57
Fig. (20):	Funnel plot of (recurrence rate) on Aflibercept group vs Control group – Odds Ratio (publication bias was non-significant).	57
Fig. (21):	Forest plot of (complications rate) on Aflibercept group vs Control group – Odds Ratio.....	59
Fig. (22):	Funnel plot of (complications rate) on Aflibercept group vs Control group – Odds Ratio (publication bias was significant).....	59
Fig. (23):	Forest plot of (BCVA) on Bevacizumab group vs Control group - Mean difference.	61
Fig. (24):	Funnel plot of (BCVA) on Bevacizumab group vs Control group - Mean difference (publication bias was significant).....	61

Fig. (25):	Forest plot of (CRT decrease) on Bevacizumab group vs Control group - Mean difference.....	63
-------------------	--	----

List of Figures Cont...

Fig. No.	Title	Page No.
Fig. (26):	Funnel plot of (CRT decrease) on Bevacizumab group vs Control group - Mean difference (publication bias was non-significant).....	63
Fig. (27):	Forest plot of (complications rate) on Bevacizumab group vs Control group – Odds Ratio.....	65
Fig. (28):	Funnel plot of (complications rate) on Bevacizumab group vs Control group – Odds Ratio (publication bias was non-significant).	65
Fig. (29):	Forest plot of (BCVA) on Ranibizumab group vs Control group - Mean difference.	67
Fig. (30):	Funnel plot of (BCVA) on Ranibizumab group vs Control group - Mean difference (publication bias was significant).....	67
Fig. (31):	Forest plot of (CRT decrease) on Ranibizumab group vs Control group - Mean difference.....	69
Fig. (32):	Funnel plot of (CRT decrease) on Ranibizumab group vs Control group - Mean difference (publication bias was significant).	69
Fig. (33):	Forest plot of (complications rate) on Ranibizumab group vs Control group – Odds Ratio.....	71
Fig. (34):	Funnel plot of (complications rate) on Ranibizumab group vs Control group – Odds Ratio (publication bias was non-significant).	71

